«

»

Quick Look: Antiretroviral Price Increases in Medicare Part D

Drug price concerns in the U.S., including for antiretrovirals, the mainstay of HIV treatment and, increasingly prevention, have prompted the introduction of several policy proposals. One proposal would require manufacturers to provide a rebate to the federal government if prices increase faster than inflation. We assessed list price changes for ARVs under Part D, which is required to cover all or substantially all ARVs.

Read the full post at Reports on Health Insurance and Health Care Costs from the Kaiser Family Foundation
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive